CURRENT POSSIBILITIES FOR EFFECTIVE TREATMENT OF VULVOVAGINAL CANDIDIASIS

Objective. To evaluate the clinical and microbiological efficacy and safety of fenticonazole (lomexin) used in women with vulvovaginal candidiasis (VVC). Subjects and methods. Thirty women of reproductive age (18—45 years old) with the verified diagnosis of VVC were examined using a general clinical study, microscopy of gram-stained smears, a cultural study of vaginal discharge, polymerase chain reaction, and expanded colposcopy. Lomexin was used in a daily dose of 600 mg as vaginal capsules twice at an interval of 3 days. A control examination was made 7—10 days and 1 month after its administration. Results. The eff iciency of Lomexin use was 96.7%. All the patients (100%) reported considerable positive changes just on days 2—3 of therapy. Manifestations, such as itch, burning, discomfort, and dysuria, were most rapidly relieved. A colposcopic re-examination revealed a positive effect in 22 (73.3%) of the 30 patients with varying degrees of exocervicitis after the therapy performed. No drug-related adverse reactions were observed in any case. Conclusion. Lomexin is an effective agent to treat VVC, well tolerated, easy-to-use, and highly acceptable.

vulvovaginal candidiasis, fenticonazole, lomexin, efficacy, safety